$LGND news
The latest LGND stock news: headlines, filings, AI summaries and sentiment for $LGND, updated around the clock.
- LIGAND PHARMACEUTICALS INC - 10-Q Filing
- Ligand Pharmaceuticals Reports Strong Q3 2026 Results and Raises Full-Year EPS Guidance
- Ligand Pharmaceuticals Raises 2026 Adjusted EPS Guidance Amid Strong Royalty Growth
- Ligand Pharmaceuticals Reports Q3 Earnings Beat and Raises 2026 Adjusted EPS Guidance
- LIGAND PHARMACEUTICALS INC - 8-K Filing
- Ligand Pharmaceuticals (LGND) Scheduled to Report Q3 2026 Earnings
- Barclays Initiates Outperform Rating for Ligand Pharmaceuticals Amid Biopharma Royalty Aggregation Strategy
- Ligand Pharmaceuticals Enters Financing Agreement with AvenCell Therapeutics Worth Up to $47M
- LIGAND PHARMACEUTICALS INC - 8-K Filing
- LIGAND PHARMACEUTICALS INC - 8-K Filing
- LIGAND PHARMACEUTICALS INC - 8-K Filing
- Citi Resumes Buy Rating on Ligand Pharmaceuticals Following Acquisition of XOMA Royalty
- LIGAND PHARMACEUTICALS INC - 8-K Filing
- Agenus Secures Up to $340M Financing for Colon Cancer Trial, Shares Surge
- Agenus Announces $340 Million Financing Package
- Ligand Pharmaceuticals Prices $625M Convertible Debt Offering
- Ligand Pharmaceuticals Announces Proposed $550 Million Convertible Senior Notes Offering
- LIGAND PHARMACEUTICALS INC - 8-K Filing
- Insider at Ligand Pharmaceuticals Sells Shares Worth $1.1 Million
- Ligand Pharmaceuticals Insider Sells Shares for $1.1 Million
- LIGAND PHARMACEUTICALS INC - 8-K Filing
- Ligand (LGND) Q1 2026 Earnings Call Summary
- LIGAND PHARMACEUTICALS INC - 10-Q Filing
- Villere St Denis Sells $9.3 Million Worth of Tidewater Shares
- Villere St Denis Sells $9.3 Million in Tidewater Shares
- Ligand Pharmaceuticals Acquires XOMA Royalty for $39/Share, Raises 2026 Guidance
- Ligand Pharmaceuticals Acquires Xoma Royalty for $739 Million
- Ligand Pharmaceuticals to Acquire XOMA Royalty for $39 Per Share
- Ligand Pharmaceuticals to Acquire XOMA Royalty in $740 Million All-Cash Deal